menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

15 29
23.01.2025
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

© Fortune